Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis

Benralizumab is currently in clinical development for relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA, formally known as Churg-Strauss Syndrome, is a rare disease characterised by blood vessel inflammation. This inflammation can restrict blood flow to organs and tissues, sometimes permanently damaging them. Relapsed refers to a disease that has come back, and refractory refer to a disease that stopped responding to a treatment. The symptoms of EGPA can include, but are not limited to, severe asthma, bowel trouble, blood loss and anaemia. There are limited, effective treatment options for patients with relapsing EGPA.